Search
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma
Phosphate ion
go.drugbank.com/drugs/DB14523InvestigationalMixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1000 ML, PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 1500 MLNitrofural
go.drugbank.com/drugs/DB00336ApprovedVet approvedWithdrawnNitrofural or nitrofurazone is a topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial wounds, burns, ulcers, and skin infections. Nitrofural has also been administered orally...
Bisphosphocin Nu-3
go.drugbank.com/drugs/DB16015InvestigationalBisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Synonyms: Nu-3, Bisphosphocin Nu-3Pegmusirudin
go.drugbank.com/drugs/DB19220InvestigationalPegmusirudin is under investigation in clinical trial NCT00074620 (A Clinical Study to Assess the Safety of Peg-hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis).
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Bizalimogene ralaplasmid
go.drugbank.com/drugs/DB16113InvestigationalBizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related
AVR-RD-01
go.drugbank.com/drugs/DB17651InvestigationalAVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.
Carbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedThe structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.
ABX1100
go.drugbank.com/drugs/DB17655InvestigationalIt was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]